Traditional Chinese medicine composition and application thereof in low-deuterium small-molecular-group compound wine

Abstract

The invention discloses a traditional Chinese medicine composition and application thereof in low-deuterium small molecular group compound wine. The traditional Chinese medicine composition is prepared from the following components in parts by mass: 40 parts of an anti-tumor compound, 50-70 parts of rhizoma polygonati, 50-75 parts of fructus lycii, 45-65 parts of herba cistanche and 2-7 parts of fructus ziziphi jujubae, the anti-tumor compound is prepared from antrodia camphorata and ganoderma lucidum according to the mass ratio of (2-4): 1. The traditional Chinese medicine composition and the small-molecular-group low-deuterium compound wine prepared from the traditional Chinese medicine composition have the advantages that the negative influence of traditional Chinese liquor on human health is remarkably relieved, and the effects of nourishing the liver, tonifying the kidney, regulating both the liver and the kidney, regulating blood sugar and blood fat, improving vascular permeability, improving immunity and inhibiting tumors are achieved for a liquor product through the traditional Chinese medicine composition and the small-molecular-group low-deuterium compound wine prepared from the traditional Chinese medicine composition; and 2) experiments show that the traditional Chinese medicine composition provided by the invention obviously improves the inhibition rate of natural traditional Chinese medicines on liver cancer HepG2 cells.

Description

Technical Field

[0001] The invention relates to a traditional Chinese medicine compound, in particular to a traditional Chinese medicine compound suitable for preparing blended wine. Background Art

[0002] Current mainstream anti-tumor approaches (chemotherapy, radiotherapy, and targeted therapy) are generally plagued by issues such as high toxicity, increased drug resistance, and high costs. Natural medicines, due to their multi-target and low toxicity profile, have become a research hotspot. However, single plant extracts often have limited activity, making it difficult to achieve optimal therapeutic effects.

[0003] While studies have shown that triterpenes (such as Antcin K) and polysaccharides in Antrodia cinnamomea can induce apoptosis in tumor cells (e.g., HepG2 liver cancer cells), their poor water solubility, low bioavailability, and the high cost of high-purity extracts limit their clinical application. Traditional literature records that Ganoderma lucidum (Lingzhi) boasts the benefits of "prolonged consumption for weight loss and longevity." Modern research suggests that its mycelial metabolites contain antioxidants such as β-glucan and ganoderic acid. However, their antitumor activity when used alone is weak, and the mechanism of action is unclear. Traditional antitumor formulas (such as those containing Astragalus and Angelica) primarily focus on strengthening the body's immune system, but are insufficient in directly inhibiting tumor cell proliferation.

[0004] Research has shown that the deuterium content in natural water is typically around 150 ppm. High deuterium levels can block mitochondrial metabolic pathways (blocking once every 4.2 seconds), hindering energy synthesis. Deuterium-depleted water (such as 122 ppm) reduces deuterium levels and optimizes mitochondrial function, thereby enhancing cellular energy metabolism and repair, and preventing diseases caused by metabolic disorders. Some studies have suggested that excessive deuterium concentrations may be a potential cause of cancer and chronic diseases (for example, research by Hungarian scholar Gábor Somlyai has sparked interest in the anti-cancer potential of deuterium-depleted water). High deuterium levels can disrupt mitochondrial function, leading to abnormal cell proliferation (such as cancer) or metabolic disorders (such as cardiovascular disease).

[0005] Deuterium-low liquor refers to a type of baijiu (white spirit) blended with deuterium-low water, either from a base liquor or a base liquor that has undergone treatment (such as aging, purification, or cavitation). For example, patent publication number CN116218626A discloses a small-molecule deuterium-low liquor and its preparation process, which utilizes "deuterium-low water" with a deuterium content below 150 ppm to blend the low-molecule liquor. Deuterium-low liquor's primary benefits are to mitigate alcohol toxicity, reduce the risk of alcoholic liver damage, improve pancreatic cell function, and assist in blood sugar control. Due to its antioxidant and liver-protective properties, deuterium-low liquor has filled a niche in the healthy alcohol market and has received industry recognition, including the "Qingzhu Award." Research by institutions such as the Sichuan Academy of Social Sciences and the Shanghai Research Institute of Chemical Industry has confirmed the biological effects of deuterium-low liquor in regulating the nervous system and protecting the cardiovascular system. Summary of the Invention

[0006] In order to solve the problem of low inhibition rate of existing natural Chinese medicines or Chinese medicine compositions on tumor cells, reduce the damage of liquor products to human health, and enrich the efficacy of existing liquor products, the present invention provides a Chinese medicine composition and its application in the preparation of low-deuterium small molecular cluster liquor.

[0007] The technical solution adopted by the present invention is: a traditional Chinese medicine composition, comprising the following components in the following mass proportions: 40 parts of an anti-tumor compound, 50-70 parts of polygonatum, 50-75 parts of wolfberry, 45-65 parts of cistanche, and 2-7 parts of jujube; the anti-tumor compound is composed of Antrodia cinnamomea and Gastrodia elata in a mass ratio of 2-4:1.

[0008] As those skilled in the art will appreciate, the Antrodia camphorata (Taiwanofungus camphoratus) described herein is a medicinal fungus native to Taiwan, China. Despite their similar names, Antrodia camphorata and Ganoderma lucidum are actually two completely different fungi. Antrodia camphorata contains over 200 triterpenoid compounds, while a single strain of Ganoderma lucidum typically contains only 20 to 50. Antrodia camphorata not only has a greater variety of triterpenoids but also boasts over 15 times the triterpenoid content of Ganoderma lucidum, demonstrating anti-inflammatory, antioxidant, and anti-tumor properties. Ganoderma lucidum, on the other hand, is rich in Ganoderma polysaccharides and ganoderic acid, demonstrating immune-regulating, sedative, and anti-aging properties.

[0009] Those skilled in the art will understand that the Ganoderma lucidum described herein, also known as "meat Ganoderma," typically grows underground. The core differences between Ganoderma and Ganoderma lucidum lie in their biological classification, morphological characteristics, and growth environment. Ganoderma lucidum is a traditional medicinal fungus belonging to the Polyporaceae family; Ganoderma lucidum (meat Ganoderma) is a conglomerate composed of slime molds, bacteria, and fungi, classified as a fourth life form. The two differ significantly in appearance, growth characteristics, and efficacy.

[0010] The traditional Chinese medicine composition of the present invention can further preferably be composed of the following components in the following mass ratio: 40 parts of anti-tumor complex, 60 parts of polygonatum, 60 parts of wolfberry, 60 parts of cistanche, and 5 parts of jujube; the anti-tumor complex is composed of Antrodia cinnamomea and Tai Sui in a mass ratio of 3:1.

[0011] The traditional Chinese medicine composition disclosed herein can be used to prepare blended alcoholic beverages. For example, the present invention further discloses a method for preparing a blended alcoholic beverage containing low-deuterium small-molecule Antrodia cinnamomea and Tai Sui, which utilizes the traditional Chinese medicine composition as a raw material. For example, a traditional extraction method can be employed, where the traditional Chinese medicine composition is placed in low-deuterium small-molecule liquor for extraction to obtain the desired blended alcoholic beverage (other methods may also be employed, such as first preparing the medicinal solution and then adding it to the liquor). Specifically, the method can be implemented as follows:

[0012] S1. Measure each raw material according to the mass ratio of the traditional Chinese medicine composition;

[0013] S2, grinding Antrodia cinnamomea and Ganoderma lucidum to 30-65 mesh size, and then mixing with Polygonatum sibiricum, Lycium barbarum, Cistanche deserticola, and jujube to obtain a mixture;

[0014] S3, adding the mixture to deuterium-depleted small molecular cluster liquor, and storing the mixture in a sealed container at 18-27° C. in the dark for at least 30 days to obtain an extraction complex;

[0015] S4. The liquid phase obtained by solid-liquid separation of the extracted complex is the low-deuterium small molecular cluster Antrodia cinnamomea Tai Sui prepared wine.

[0016] More preferably, the low-deuterium small-molecular-cluster liquor meets the following requirements: deuterium content ≤ 50 ppm, molecular cluster half-peak width ≤ 48 Hz; and alcohol content 50-55°.

[0017] Those skilled in the art will appreciate that when using the extraction method to produce blended liquor, the ratio of the extract to the extract (wine) should be determined based on efficacy and taste, preferably taking both taste and efficacy into account. For example, a preferred embodiment is provided: in step S3, the mass ratio of the mixture to the deuterium-depleted small molecular cluster liquor is 200-350:1000. Technicians may also make appropriate adjustments based on product market demand, and this will not be further elaborated here.

[0018] Those skilled in the art will appreciate that the deuterium-depleted small-molecule liquor used in the present invention can be produced using existing relevant production technologies, such as the small-molecule deuterium-depleted liquor and preparation process disclosed in Publication No. CN116218626A mentioned in the background technology. A specific production process is provided herein, which can be implemented by a skilled person according to the following steps. The deuterium-depleted small-molecule liquor is prepared according to the following steps:

[0019] A. Allow the base wine to stand for more than 7 days to obtain aged wine;

[0020] B. The aged wine is subjected to cavitation treatment to reduce the size of wine molecular clusters, and then subjected to filtration and purification treatment to obtain a primary treated wine;

[0021] C. adding small molecular cluster deuterium-depleted water to the primary treated wine according to the target alcohol content to obtain a secondary treated wine;

[0022] D. placing the secondary treated liquor in the aging container and allowing it to stand for aging for more than 56 days to obtain low-deuterium small molecular cluster liquor.

[0023] As will be readily understood, the aforementioned cavitation treatment is typically performed using cavitation equipment. The purpose of this cavitation equipment is to disrupt the hydrogen bonds between water and alcohol molecules in the wine, thereby partially breaking the original molecular association structure and reducing the size of molecular clusters, converting large clusters into nanoscale small clusters, resulting in a more uniform and smooth wine. This not only improves the wine's taste, reducing its pungency and making it more mellow and smooth, but also accelerates the mixing and reaction of various components in the wine, improving its quality and stability. Those skilled in the art can select cavitation equipment that meets these requirements.

[0024] The invention also discloses a low-deuterium small-molecule Antrodia cinnamomea and Tai Sui blended wine, which is prepared by the preparation method of the low-deuterium small-molecule Antrodia cinnamomea and Tai Sui blended wine of the invention.

[0025] The beneficial effects of the present invention are as follows: 1) The traditional Chinese medicine composition provided by the present invention and the small molecular cluster deuterium-deficient liquor prepared using it as raw material not only significantly reduce the negative impact of traditional liquor on human health, but also endow the liquor product with the efficacy of nourishing the liver and kidneys, regulating both the liver and kidneys, regulating blood sugar and blood lipids, improving vascular permeability, enhancing immunity, and inhibiting tumors. 2) Experiments have shown that the traditional Chinese medicine composition of the present invention significantly increases the inhibition rate of natural traditional Chinese medicine on HepG2 liver cancer cells. DETAILED DESCRIPTION

[0026] The present invention is further described below with reference to the embodiments.

[0027] The low-deuterium small molecular cluster liquors used in the following examples and comparative examples were all prepared according to the following method:

[0028] (1) Select small glutinous sorghum without pesticide residues, soak, steam and cool it, add Daqu and carry out solid-state fermentation for 28 days, and distill to obtain 62° base wine;

[0029] (2) placing the base wine in a pottery jar and aging it for 8 days, with the ambient temperature adjusted to 20°C, to obtain aged wine;

[0030] (3) The aged wine is pumped into a cavitation treatment device for treatment. The treatment time of the cavitation treatment device is 3 hours and the treatment temperature is 50°C. The aged wine treated by the cavitation treatment device is then filtered through a 10 μm molecular sieve, an activated carbon adsorption column, and a 0.2 μm ceramic membrane in sequence to remove suspended matter and free radicals, thereby obtaining a first-processed wine.

[0031] (4) adding small molecular cluster deuterium-depleted water to the first-treated wine according to the target alcohol content of 53° to obtain a second-treated wine;

[0032] (5) The secondary treated liquor was placed in the aging container and aged for 98 days. The storage environment temperature was adjusted to 20° C. and the humidity was 70%, thereby obtaining a low-deuterium small-molecule cluster liquor. The low-deuterium small-molecule cluster liquor had an alcohol content of 53°, a deuterium content of 47 ppm as determined by IRMS, and a peak width at half maximum of 46 Hz as determined by nuclear magnetic resonance oxygen spectroscopy (17O-NMR).

[0033] Example 1:

[0034] Prepare the low-deuterium small molecular cluster Antrodia cinnamomea Tai Sui blended wine according to the following steps:

[0035] (1) The raw materials were measured according to the following mass ratio of the Chinese medicine composition: 40 parts of anti-tumor compound, 60 parts of polygonatum, 60 parts of wolfberry, 60 parts of cistanche deserticola, and 5 parts of jujube; the anti-tumor compound was composed of Antrodia cinnamomea and Gastrodia elata in a mass ratio of 3:1.

[0036] (2) Grind Antrodia cinnamomea and Ganoderma lucidum and pass through a 40-mesh sieve, then mix with Polygonatum sibiricum, Lycium barbarum, Cistanche deserticola, and jujube to obtain a mixture.

[0037] (3) adding the mixture to the deuterium-depleted small molecular cluster liquor at a mass ratio of the mixture to the deuterium-depleted small molecular cluster liquor of 280:1000, and then storing the mixture in a sealed container at 23°C in the dark for 45 days to obtain an extraction complex.

[0038] (4) The liquid phase obtained by solid-liquid separation of the extracted complex is the low-deuterium small molecular cluster Antrodia cinnamomea Tai Sui prepared wine.

[0039] Example 2:

[0040] Prepare the low-deuterium small molecular cluster Antrodia cinnamomea Tai Sui blended wine according to the following steps:

[0041] (1) The raw materials were measured according to the following mass ratio of the Chinese medicine composition: 40 parts of anti-tumor compound, 55 parts of polygonatum, 50 parts of wolfberry, 45 parts of cistanche deserticola, and 3 parts of jujube; the anti-tumor compound was composed of Antrodia cinnamomea and Gastrodia elata in a mass ratio of 4:1.

[0042] (2) Grind Antrodia cinnamomea and Ganoderma lucidum and pass through a 50-mesh sieve, then mix with Polygonatum sibiricum, Lycium barbarum, Cistanche deserticola, and jujube to obtain a mixture.

[0043] (3) adding the mixture to the deuterium-depleted small molecular cluster liquor at a mass ratio of the mixture to the deuterium-depleted small molecular cluster liquor of 250:1000, and then storing the mixture in a sealed container at 23°C in the dark for 45 days to obtain an extraction complex.

[0044] (4) The liquid phase obtained by solid-liquid separation of the extracted complex is the low-deuterium small molecular cluster Antrodia cinnamomea Tai Sui prepared wine.

[0045] Example 3:

[0046] Prepare the low-deuterium small molecular cluster Antrodia cinnamomea Tai Sui blended wine according to the following steps:

[0047] (1) The raw materials were measured according to the following mass ratio of the Chinese medicine composition: 40 parts of anti-tumor compound, 65 parts of polygonatum, 75 parts of wolfberry, 55 parts of cistanche deserticola, and 7 parts of jujube; the anti-tumor compound was composed of Antrodia cinnamomea and Gastrodia elata in a mass ratio of 2.5:1.

[0048] (2) Grind Antrodia cinnamomea and Ganoderma lucidum and pass through a 40-mesh sieve, then mix with Polygonatum sibiricum, Lycium barbarum, Cistanche deserticola, and jujube to obtain a mixture.

[0049] (3) adding the mixture to the deuterium-depleted small molecular cluster liquor at a mass ratio of the mixture to the deuterium-depleted small molecular cluster liquor of 300:1000, and then storing the mixture in a sealed container at 23°C in the dark for 45 days to obtain an extraction complex.

[0050] (4) The liquid phase obtained by solid-liquid separation of the extracted complex is the low-deuterium small molecular cluster Antrodia cinnamomea Tai Sui prepared wine.

[0051] Comparative Example 1:

[0052] This comparative example is a control experiment of Example 1, carried out according to the same steps and conditions as Example 1. All raw materials are from the same batch as in Example 1. The only difference is that ordinary 53° liquor (measured deuterium content of 157 ppm and half-peak width of the molecular clusters of 116 Hz) is used instead of the low-deuterium small-cluster liquor in Example 1. The specific steps are as follows:

[0053] (1) The raw materials were measured according to the following mass ratio of the Chinese medicine composition: 40 parts of anti-tumor compound, 60 parts of polygonatum, 60 parts of wolfberry, 60 parts of cistanche deserticola, and 5 parts of jujube; the anti-tumor compound was composed of Antrodia cinnamomea and Gastrodia elata in a mass ratio of 3:1.

[0054] (2) Grind Antrodia cinnamomea and Ganoderma lucidum and pass through a 40-mesh sieve, then mix with Polygonatum sibiricum, Lycium barbarum, Cistanche deserticola, and jujube to obtain a mixture.

[0055] (3) The mixture was added to the ordinary 53° liquor, with the mass ratio of the mixture to the low-deuterium small molecular cluster liquor being 280:1000, and then stored in a sealed container at 23°C in the dark for 45 days to obtain an extraction complex.

[0056] (4) The liquid phase obtained by solid-liquid separation of the extracted complex is the prepared liquor.

[0057] Comparative Example 2:

[0058] This comparative example is a control experiment of Example 1, and is carried out according to the same steps and conditions as Example 1. All raw materials are from the same batch as in Example 1. The only difference is that the anti-tumor agent is all Antrodia cinnamomea (the total amount of anti-tumor agent remains unchanged). The specific steps are as follows:

[0059] (1) Measure the raw materials according to the following mass ratio of the Chinese medicine composition: 40 parts of Antrodia cinnamomea, 60 parts of Polygonatum sibiricum, 60 parts of Lycium barbarum, 60 parts of Cistanche deserticola, and 5 parts of jujube.

[0060] (2) Grind Antrodia cinnamomea and Ganoderma lucidum and pass through a 40-mesh sieve, then mix with Polygonatum sibiricum, Lycium barbarum, Cistanche deserticola, and jujube to obtain a mixture.

[0061] (3) adding the mixture to the deuterium-depleted small molecular cluster liquor at a mass ratio of the mixture to the deuterium-depleted small molecular cluster liquor of 280:1000, and then storing the mixture in a sealed container at 23°C in the dark for 45 days to obtain an extraction complex.

[0062] (4) The liquid phase obtained by solid-liquid separation of the extracted complex is the prepared liquor.

[0063] Comparative Example 3:

[0064] This comparative example is a control experiment of Example 1, carried out according to the same steps and conditions as Example 1. All raw materials are from the same batch as in Example 1. The only difference is that all anti-tumor substances are galangal (the total amount of anti-tumor substances remains unchanged). The specific steps are as follows:

[0065] (1) Measure the raw materials according to the following mass ratio of the Chinese medicine composition: 40 parts of Tai Sui, 60 parts of Polygonatum, 60 parts of Lycium barbarum, 60 parts of Cistanche deserticola, and 5 parts of jujube.

[0066] (2) Grind Antrodia cinnamomea and Ganoderma lucidum and pass through a 40-mesh sieve, then mix with Polygonatum sibiricum, Lycium barbarum, Cistanche deserticola, and jujube to obtain a mixture.

[0067] (3) adding the mixture to the deuterium-depleted small molecular cluster liquor at a mass ratio of the mixture to the deuterium-depleted small molecular cluster liquor of 280:1000, and then storing the mixture in a sealed container at 23°C in the dark for 45 days to obtain an extraction complex.

[0068] (4) The liquid phase obtained by solid-liquid separation of the extracted complex is the prepared liquor.

[0069] Comparative experiment on the inhibition rate of HepG2 liver cancer cell proliferation:

[0070] The inhibition rates of the blended liquors of each embodiment and each comparative example on the proliferation of liver cancer HepG2 cells were compared and detected by MTT assay.

[0071] (1) Experimental group (see Table 1):

[0072] Table 1 Experimental group registration form

[0073] Group Processing content Blank control group Culture medium only Negative control group Cells + 0.1% DMSO (solvent control) Treatment group 1 Cells + prepared liquor of Example 1, concentration 400 μg / mL Treatment group 2 Cells + prepared liquor of Example 2, concentration 400 μg / mL Treatment group 3 Cells + prepared liquor of Example 3, concentration 400 μg / mL Control group 1 Cells + Comparative Example 1 blended liquor, concentration 400 μg / mL Control group 2 Cells + Comparative Example 2 blended liquor, concentration 400 μg / mL Control group 3 Cells + Comparative Example 3 blended liquor, concentration 400 μg / mL

[0074] (2) HepG2 cells in the logarithmic growth phase were obtained, digested with trypsin, and then the density was adjusted to: adherent cells: 5 × 10³ cells / well (96-well plate, 200 μL complete medium per well); cultured at 37°C, 5% CO2 for 24 hours to allow the cells to adhere and enter the exponential proliferation phase.

[0075] (3) Aspirate and discard the old culture medium. Add fresh culture medium (200 μL / well) as described in Table 1 to each group for 48 h.

[0076] (4) Add 20 μL of MTT solution (5 mg / mL, prepared in PBS) to each well, with a final concentration of 0.5 mg / mL; incubate at 37°C in the dark for 4 hours; carefully discard the supernatant, add 150 μL of DMSO to each well, and shake at low speed for 10 minutes to dissolve the crystals.

[0077] (5) Measure the absorbance at 570 nm using a microplate reader (OD 570 ), the reference wavelength was 630nm and the background was subtracted. The blank control group was recorded as OD B , the negative control group was recorded as OD N OD T .

[0078] (6) Calculate the cell proliferation inhibition rate of each treatment group and the control group according to the following formula:

[0079]

[0080] The results are shown in Table 2:

[0081] Table 2 Comparison of HepG2 cell proliferation inhibition rates in the treatment and control groups

[0082] HepG2 cell proliferation inhibition rate Treatment group 1 73.87% Treatment group 2 71.45% Treatment group 3 64.50% Control group 1 56.21% Control group 2 44.76% Control group 3 13.65%

[0083] From the test results of treatment group 1, treatment group 2 and treatment group 3 in Table 2, it can be seen that the low-deuterium small molecular cluster Antrodia cinnamomea Tai Sui blended wine of the present invention can inhibit the proliferation of liver cancer HepG2 cells by more than 70%, which has a very obvious inhibitory effect.

[0084] A comparison of treatment group 1 and control group 1 in Table 2 shows that when the ordinary liquor extractant in control group 1 was replaced with the same mass ratio of deuterium-depleted small-molecule liquor, the HepG2 cell proliferation inhibition rate increased from 56.21% to 73.87%. The inventors believe that this may be related to the fact that deuterium-depleted small-molecule liquor can significantly increase the dissolution rate of some active ingredients in traditional Chinese medicine.

[0085] Comparison of treatment group 1, control group 2, and control group 3 in Table 2 shows that, with identical dosages of the anti-tumor agents, the HepG2 cell proliferation inhibition rate in control group 2, which used Antrodia cinnamomea alone, was 44.76%, while the HepG2 cell proliferation inhibition rate in control group 3, which used Antrodia cinnamomea alone, was 13.65%. The inhibition rate in treatment group 1, which combined the two, reached 73.87%, demonstrating a significant synergistic effect between the components of the anti-tumor complex of the present invention in increasing the HepG2 cell proliferation inhibition rate.

Claims

1. A Chinese medicine composition, characterized in that The invention comprises the following components in the following mass proportions: 40 parts of anti-tumor compound, 50-70 parts of polygonatum, 50-75 parts of wolfberry, 45-65 parts of cistanche deserticola, and 2-7 parts of jujube; The anti-tumor complex is composed of Antrodia cinnamomea and Ganoderma lucidum in a mass ratio of 2 to 4:

1.

2. The Chinese medicine composition according to claim 1, characterized in that The invention comprises the following components in the following mass proportions: 40 parts of anti-tumor compound, 60 parts of polygonatum, 60 parts of wolfberry, 60 parts of cistanche deserticola, and 5 parts of jujube; the anti-tumor compound is composed of antrodia cinnamomea and tsaoko in a mass ratio of 3:

1.

3. A method for preparing a low-deuterium small molecular group Antrodia cinnamomea Tai Sui blended wine, characterized by: The production raw materials include the traditional Chinese medicine composition of claim 1 or 2.

4. The method for preparing the low-deuterium small molecular group Antrodia cinnamomea Tai Sui blended wine according to claim 3, characterized in that: The method comprises the steps of placing the traditional Chinese medicine composition in low-deuterium small molecular cluster liquor for extraction.

5. The method for preparing the low-deuterium small molecular group Antrodia cinnamomea Tai Sui blended wine according to claim 4, characterized in that: The steps include: S1. Measure each raw material according to the mass ratio of the traditional Chinese medicine composition; S2, grinding Antrodia cinnamomea and Ganoderma lucidum to 30-65 mesh size, and then mixing with Polygonatum sibiricum, Lycium barbarum, Cistanche deserticola, and jujube to obtain a mixture; S3, adding the mixture to deuterium-depleted small molecular cluster liquor, and storing the mixture in a sealed container at 18-27° C. in the dark for at least 30 days to obtain an extraction complex; S4. The liquid phase obtained by solid-liquid separation of the extracted complex is the low-deuterium small molecular cluster Antrodia cinnamomea Tai Sui prepared wine.

6. The method for preparing the low-deuterium small molecular group Antrodia cinnamomea Tai Sui blended wine according to claim 4 or 5, characterized in that: The low-deuterium small-molecular-cluster liquor meets the following requirements: deuterium content ≤ 50 ppm, molecular cluster half-peak width ≤ 48 Hz; and alcohol content 50-55°.

7. The method for preparing the low-deuterium small molecular group Antrodia cinnamomea Tai Sui blended wine according to claim 6, characterized in that: In step S3, the mass ratio of the mixture to the deuterium-depleted small molecular cluster liquor is 200-350:1000.

8. The method for preparing the low-deuterium small molecular group Antrodia cinnamomea Tai Sui blended wine according to claim 4 or 5, characterized in that: The low-deuterium small molecular cluster liquor is prepared according to the following steps: A. Allow the base wine to stand for more than 7 days to obtain aged wine; B. The aged wine is subjected to cavitation treatment to reduce the size of wine molecular clusters, and then subjected to filtration and purification treatment to obtain a primary treated wine; C. adding small molecular cluster deuterium-depleted water to the primary treated wine according to the target alcohol content to obtain a secondary treated wine; D. placing the secondary treated liquor in the aging container and allowing it to stand for aging for more than 56 days to obtain low-deuterium small molecular cluster liquor.

9. A low-deuterium small-molecule Antrodia cinnamomea and Tai Sui prepared wine prepared by the method for preparing a low-deuterium small-molecule Antrodia cinnamomea and Tai Sui prepared wine according to any one of claims 3 to 8.

Images